Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1)

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chufan, Eduardo E ^a   Kapoor, Khyati ^a   Sim, Hong May ^a   Singh, Satyakam ^b   Talele, Tanaji T ^b   Durell, Stewart R ^a   Ambudkar, Suresh A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' FLUOROSULFONYLBENZOYL 5' ADENOSINE; ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; CYSTEINE; GLUTAMINE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; PACLITAXEL; PHENYLALANINE; SULFUR DERIVATIVE; TARIQUIDAR; TYROSINE; UNCLASSIFIED DRUG; VALINE; VALINOMYCIN;

AMINO ACID SUBSTITUTION; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG TRANSPORT; HELA CELL; HUMAN; HUMAN CELL; HYDROLYSIS; INSECT CELL; MAMMAL CELL; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RESIDUE ANALYSIS; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; BINDING SITES; CELL LINE, TUMOR; FLUORESCENT DYES; GENE EXPRESSION; HELA CELLS; HUMANS; HYDROLYSIS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; TRANSDUCTION, GENETIC;

EID: 84891912095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082463     Document Type: Article

References (57)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398. doi: 10.1146/annurev.pharmtox.39.1.361. PubMed: 10331089. (Pubitemid 29222564)
2. Ambudkar SV, Kim IW, Sauna ZE (2006) The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27: 392-400. doi:10.1016/j.ejps.2005.10.010. PubMed: 16352426. (Pubitemid 43363335)
3. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234. doi:10.1038/nrd1984. PubMed: 16518375. (Pubitemid 43336035)
4. Blatter XL, Seelig A (2010) Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers. Biophys J 99: 3589-3598. doi: 10.1016/j.bpj.2010.10.033. PubMed: 21112283.
5. Gutmann DAP, Ward A, Urbatsch IL, Chang G, van Veen HW (2010) Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends Biochem Sci 35: 36-42. doi:10.1016/ j.tibs.2009.07.009. PubMed: 19819701.
6. Sharom FJ (2011) The P-glycoprotein multidrug transporter. Essays Biochem 50: 161-178. doi:10.1042/bse0500161. PubMed: 21967057.
7. Seeger MA, van Veen HW (2009) Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 1794: 725-737. doi:10.1016/j.bbapap.2008. 12.004. PubMed: 19135557.
8. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A 94: 10594-10599. doi: 10.1073/pnas.94.20.10594. PubMed: 9380680.
9. Loo TW, Bartlett MC, Clarke DM (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278: 39706-39710. doi:10.1074/ jbc.M308559200. PubMed: 12909621. (Pubitemid 37248532)
10. Loo TW, Clarke DM (2001) Determining the dimensions of the drugbinding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 276: 36877-36880. doi: 10.1074/jbc.C100467200. PubMed: 11518701.
11. Loo TW, Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem 276: 14972-14979. doi:10.1074/jbc. M100407200. PubMed: 11279063.
12. Lugo MR, Sharom FJ (2005) Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: Evidence for simultaneous binding of both drugs. Biochemistry 44: 14020-14029. doi:10.1021/bi0511179. PubMed: 16229491. (Pubitemid 41507482)
13. Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250: 130-137. doi:10.1111/j.1432-1033.1997.00130.x. PubMed: 9432000. (Pubitemid 27504592)
14. Shapiro AB, Fox K, Lam P, Ling V (1999) Stimulation of P-glycoproteinmediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259: 841-850. PubMed: 10092872. (Pubitemid 29075514)
15. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P et al. (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58: 624-632. PubMed: 10953057.
16. Safa AR (2004) Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4: 1-17. doi: 10.2174/1568011043482142. PubMed: 14754408. (Pubitemid 38081746)
17. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722. doi:10.1126/science.1168750. PubMed: 19325113.
18. Marcoux J, Wang SC, Politis A, Reading E, Ma J et al. (2013) Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proc Natl Acad Sci U S A 110: 9704-9709. doi:10.1073/pnas.1303888110. PubMed: 23690617.
19. Tao HC, Weng Y, Zhuo RP, Chang G, Urbatsch IL et al. (2011) Design and synthesis of selenazole-containing peptides for cocrystallization with P-glycoprotein. Chembiochem 12: 868-873. doi:10.1002/cbic. 201100048. PubMed: 21387512.
20. Martin C, Berridge G, Mistry P, Higgins C, Charlton P et al. (1999) The molecular interaction of the high affinity reversal agent XR9576 with Pglycoprotein. Br J Pharmacol 128: 403-411. doi:10.1038/sj.bjp. 0702807. PubMed: 10510451. (Pubitemid 29458600)
21. Ohnuma S, Chufan E, Nandigama K, Jenkins LMM, Durell SR et al. (2011) Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5 '-Fluorosulfonylbenzoyl 5 '-adenosine: Evidence for an ATP analogue that interacts with both drug-substrate-and nucleotidebinding sites. Biochemistry 50: 3724-3735. doi:10.1021/bi200073f. PubMed: 21452853.
22. Loo TW, Clarke DM (1995) Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem 270: 843-848. doi: 10.1074/jbc.270.2.843. PubMed: 7822320.
23. Greenberger LM, Yang CP, Gindin E, Horwitz SB (1990) Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394-4401. PubMed: 1968459.
24. Loo TW, Clarke DM (2008) Mutational analysis of ABC proteins. Arch Biochem Biophys 476: 51-64. doi:10.1016/j.abb.2008.02.025. PubMed: 18328253.
25. Loo TW, Clarke DM (2002) Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277: 44332-44338. doi:10.1074/jbc.M208433200. PubMed: 12223492. (Pubitemid 36157868)
26. Taylor AM, Storm J, Soceneantu L, Linton KJ, Gabriel M et al. (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 134: 1609-1618. doi:10.1038/sj.bjp.0704400. PubMed: 11739236. (Pubitemid 34038093)
27. Loo TW, Bartlett MC, Detty MR, Clarke DM (2012) The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together. J Biol Chem 287: 26806-26816. doi:10.1074/ jbc.M112.376202. PubMed: 22700974.
28. Kerr KM, Sauna ZE, Ambudkar SV (2001) Correlation between steadystate ATP hydrolysis and vanadate-induced ADP trapping in human Pglycoprotein - Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 276: 8657-8664. doi:10.1074/jbc. M010044200. PubMed: 11121420.
29. Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW et al. (2011) The "Specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci 2: 82-89. doi:10.1021/cn100078a. PubMed: 22778859.
30. Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV (2012) Use of Baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab Dispos 40: 304-312. doi: 10.1124/dmd.111.042721. PubMed: 22041108.
31. Jin MS, Oldham ML, Zhang QJ, Chen J (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490: 566-570. doi:10.1038/nature11448. PubMed: 23000902.
32. Ward AB, Szewczyk P, Grimard V, Lee CW, Martinez L et al. (2013) Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A 110: 13386-13391. doi:10.1073/pnas.1309275110. PubMed: 23901103.
33. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461. PubMed: 19499576.
34. Loo TW, Bartlett MC, Clarke DM (2003) Substrate-induced conformational, changes in the transmembrane segments of human Pglycoprotein - Direct evidence for the substrate-induced fit mechanism for drug binding. J Biol Chem 278: 13603-13606. doi:10.1074/ jbc.C300073200. PubMed: 12609990. (Pubitemid 36799891)
35. Dolghih E, Bryant C, Renslo AR, Jacobson MP (2011) Predicting Binding to P-glycoprotein by flexible receptor docking. PLoS Comput Biol 7 (6): e1002083. PubMed: 21731480.
36. Klepsch F, Chiba P, Ecker GF (2011) Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of Pglycoprotein. PLoS Comput Biol 7 (5): e1002036. PubMed: 21589945.
37. Ward A, Reyes CL, Yu J, Roth CB, Chang G (2007) Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci U S A 104: 19005-19010. doi:10.1073/pnas.0709388104. PubMed: 18024585.
38. Loo TW, Bartlett MC, Clarke DM (2009) Identification of residues in the drug translocation pathway of the human multidrug resistance Pglycoprotein by Arginine mutagenesis. J Biol Chem 284: 24074-24087. doi:10.1074/jbc.M109.023267. PubMed: 19581304.
39. Loo TW, Bartlett MC, Clarke DM (2006) Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 399: 351-359. doi:10.1042/BJ20060715. PubMed: 16813563. (Pubitemid 44570297)
40. Loo TW, Clarke DM (1997) Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem 272: 31945-31948. doi:10.1074/jbc.272.51.31945. PubMed: 9405384. (Pubitemid 28011858)
41. Loo TW, Bartlett MC, Clarke DM (2003) Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. J Biol Chem 278: 50136-50141. doi:10.1074/ jbc.M310448200. PubMed: 14522974. (Pubitemid 37548851)
42. Loo TW, Bartlett MC, Clarke DM (2003) Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drugbinding site. J Biol Chem 278: 20449-20452. doi:10.1074/ jbc.C300154200. PubMed: 12711602. (Pubitemid 36806339)
43. Al-Shawi MK (2011) Catalytic and transport cycles of ABC exporters. Essays Biochem 50: 63-83. doi:10.1042/bse0500063. PubMed: 21967052.
44. Chakraborty S, Ásgeirsson B, Rao BJ (2012) A measure of the broad substrate specificity of enzymes based on 'Duplicate' catalytic residues. PLOS ONE 7 (11): e49313. doi:10.1371/journal.pone.0049313. PubMed: 23166637.
45. Hamada H, Tsuruo T (1986) Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A 83: 7785-7789. doi: 10.1073/pnas.83.20. 7785. PubMed: 2429319. (Pubitemid 17183929)
46. Ramachandra M, Ambudkar SV, Gottesman MM, Pastan I, Hrycyna CA (1996) Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell 7: 1485-1498. doi:10.1091/ mbc.7.10.1485. PubMed: 8898356. (Pubitemid 26339723)
47. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV (2000) Functional characterization of glycosylation-deficient human Pglycoprotein using a vaccinia virus expression system. J Membr Biol 173: 203-214. doi:10.1007/s002320001020. PubMed: 10667916. (Pubitemid 30100212)
48. Sauna ZE, Müller M, Peng XH, Ambudkar SV (2002) Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human Pglycoprotein (ABCB1). Biochemistry 41: 13989-14000. doi:10.1021/ bi026626e. PubMed: 12437356. (Pubitemid 35364871)
49. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S et al. (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37: 5010-5019. doi: 10.1021/bi973045u. PubMed: 9538020. (Pubitemid 28175983)
50. Sauna ZE, Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci U S A 97: 2515-2520. doi:10.1073/pnas.97.6.2515. PubMed: 10716986. (Pubitemid 30159202)
51. Ambudkar SV (1998) Drug-stimulatable ATPase activity in crude membranes of human MDR1- transfected mammalian cells. Methods Enzymol 292: 504-514. doi:10.1016/S0076-6879(98)92039-0. PubMed: 9711578. (Pubitemid 29343911)
52. Altschul SF, Madden TL, Schäffer AA, Zhang JH, Zhang Z et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402. doi:10.1093/nar/ 25.17.3389. PubMed: 9254694. (Pubitemid 27359211)
53. Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) Procheck - a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283-291. doi:10.1107/ S0021889892009944.
54. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. PubMed: 15572765. (Pubitemid 41742764)
55. Lovell SC, Davis IW, Arendall WB, de Bakker PIW, Word JM et al. (2003) Structure validation by C alpha geometry: phi,psi and C beta deviation. Proteins 50: 437-450. doi:10.1002/prot.10286. PubMed: 12557186. (Pubitemid 36158457)
56. Brooks BR, Brooks CL 3rd, Mackerell AD Jr., Nilsson L, Petrella RJ et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30: 1545-1614. doi:10.1002/jcc.21287. PubMed: 19444816.
57. Sanner MF (1999) Python: A programming language for software integration and development. J Mol Graph Model 17: 57-61. PubMed: 10660911. (Pubitemid 30029318)